高级搜索

射波刀Cyberknife治疗无法手术切除原发性肝内胆管细胞癌疗效观察

沈泽天, 王震, 武新虎, 李兵, 朱锡旭

沈泽天, 王震, 武新虎, 李兵, 朱锡旭. 射波刀Cyberknife治疗无法手术切除原发性肝内胆管细胞癌疗效观察[J]. 肿瘤防治研究, 2015, 42(08): 818-823. DOI: 10.3971/j.issn.1000-8578.2015.08.015
引用本文: 沈泽天, 王震, 武新虎, 李兵, 朱锡旭. 射波刀Cyberknife治疗无法手术切除原发性肝内胆管细胞癌疗效观察[J]. 肿瘤防治研究, 2015, 42(08): 818-823. DOI: 10.3971/j.issn.1000-8578.2015.08.015
shu
SHEN Zetian, WANG Zhen, WU Xinhu, LI Bing, ZHU Xixu. Clinical Observation on Cyberknife Radiosurgery Treatment for Unresectable Primary Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 818-823. DOI: 10.3971/j.issn.1000-8578.2015.08.015
Citation: SHEN Zetian, WANG Zhen, WU Xinhu, LI Bing, ZHU Xixu. Clinical Observation on Cyberknife Radiosurgery Treatment for Unresectable Primary Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 818-823. DOI: 10.3971/j.issn.1000-8578.2015.08.015
shu

射波刀Cyberknife治疗无法手术切除原发性肝内胆管细胞癌疗效观察

  • 1. 210002 南京，南京军区南京总医院放疗科；2. 210002 南京，南京军区南京总医院高压氧科

详细信息
    作者简介:

    沈泽天（1981-），男，硕士，主治医师，主要从事肿瘤立定定向放射治疗的研究

    通信作者:

    朱锡旭，E-mail：simon_doctor@163.com

  • 中图分类号: R735.7

Clinical Observation on Cyberknife Radiosurgery Treatment for Unresectable Primary Intrahepatic Cholangiocarcinoma

  • 1. Department of Radiation Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China; 2. Department of Hyperbaric Oxygen, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China

摘要

    摘要
  • 摘要: 目的 观察立体定向放射治疗（SBRT）对无法手术切除原发性肝内胆管细胞癌（ICC）的疗效及不良反应。方法 对28例原发性ICC患者行射波刀SBRT，给予总剂量为45 Gy（36~54 Gy），分割3~5次，处方剂量线范围为70%~92%。按照RECIST1.1标准进行实体瘤近期疗效评价，采用Kaplanmeier方法分析生存率及疾病控制率，Cox方法进行多因素分析评价影响预后的因素, 美国放射肿瘤学协作组（RTOG 2.0）标准进行放射反应评级。结果 28例患者中，完全缓解（CR）3例（10.7%)，部分缓解（PR）10例（35.7%），无变化（SD）12例（42.9%），进展（PD）3例（10.7%），疾病有效率（CR+PR）为46.4%，疾病控制率（CR+PR+SD）为89.3％。治疗后随访3~42月，中位随访时间为16月，1、2年生存率分别为57.1%、32.1%， 28例患者的中位生存期15月（95%CI: 7.22~22.78）。所有患者对治疗耐受良好，不良反应轻微，治疗不良反应主要局限于1~2级，未出现大于3级的不良反应。多因素分析显示肿瘤直径较大、淋巴结转移、临床分期较晚可能导致较差的预后（P<0.01）。结论 对于无法手术切除的原发性ICC，射波刀SBRT疗效显著，安全性好，值得进一步临床推广。

     

    Abstract: Objective To report the outcomes of Cyberknife stereotactic body radiotherapy(SBRT) for patients with unresectable primary intrahepatic cholangiocarcinoma(ICC). Methods Twenty-eight patients with ICC were treated with Cyberknife SBRT. The median prescription dose was 45Gy(range, 36-54Gy). The prescribed radiation dosage was fractionated 3 to 5 times with a 70% to 92% isodose line. Treatment response was graded by RECIST v.1.1. The survival rate and disease control rate were compared by Kaplan- Meier analysis and toxicity was evaluated according to the Radiation Therapy Oncology Group(RTOG) Toxicity Criteria, Version 2.0. Patient records were reviewed and compared using multivariate analysis(Cox regression) to determine the factors that affected survival time of ICC patients. Results The median follow-up time was 16months (3-42 months). After SBRT, evaluated by CT or MRI, 3(10.7%) patients had complete response(CR), 10(35.7%) patients showed partial response(PR), 12(42.9%) patients were stable disease(SD), 3(10.7%) patients were progressive disease(PD). The local control rate(CR+PR) was 42.9% and disease control rate(CR+PR+SD) was 89.3%. Median survival time was 15 months (95%CI: 7.22-22.78). 1- and 2-year overall survival were 57.1% and 32.1%, respectively. Multivariate analysis revealed that larger tumor size, synchronous lymph node metastases and later clinical stage were associated with poorer prognosis(P<0.01). Toxicity mainly consisted of grade 1-2. No toxicity greater than grade 3 was observed. Conclusion Cyberknife SBRT is safe and effective for unresectable primary ICC with acceptable toxicity.

     

    • HTML全文
    • 参考文献(20)
  • [1] Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature[J]. J Am Coll Surg, 2009, 208(1): 134-47.
    [2] Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?[J]. J Hepatol, 2004, 40(3): 472-7.
    [3] Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 20 07, 37(9): 676-91.
    [4] O’Connor JK, Trotter J, Davis GL, et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl, 2012, 18(8): 949-54.
    [5] Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results[J]. Technol Cancer Res Treat, 2010, 9(5): 479-87.
    [6] Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy[J]. Radiat Oncol, 2012, 7: 166.
    [7] Bibault JE, Dewas S, Vautravers-Dewas C, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity[J]. PLoS One, 2013, 8( 10): e77472.
    [8] Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012, 84(2): 355-61.
    [9] Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis[J]. BMC Cancer, 2008, 8: 351.
    [10] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-47.
    [11] Zeng ZC, Tang ZY, Fan J, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients[J]. Cancer J, 2006, 12(2): 11 3-22.
    [12] Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients[J]. BMC Cancer, 2010, 10: 492.
    [13] Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1495-501.
    [14] Tse RV, Hawkins M, Lockwood G, et al. PhaseⅠstudy of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 20 08, 26(4): 657-64.
    [15] Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma[J]. Radiother Oncol, 2010, 94 (1): 47-52.
    [16] Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma[J]. Radiat Oncol, 2012, 3, 7: 67.
    [17] Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy[J]. Radiat Oncol, 2012, 10,7: 166.
    [18] van der Voort van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for nonsmall cell lung cancer: clinical outcome[J]. Radiother Oncol, 20 09, 91(3): 296-300.
    [19] He rbe r S, Ot to G, Schne ide r J , e t al . Tr ans a r t e r i a l chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma[J]. Cardiovasc Intervent Radiol, 2007, 30(6): 11 56-65.
    [20] Kim JM, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes[J]. Cancer, 2008, 113(7): 1614-22.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2147
  • HTML全文浏览量:  602
  • PDF下载量:  567
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-09-25
  • 修回日期:  2014-12-09
  • 刊出日期:  2015-08-24

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：19064625 今日访问：38519

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭

    声明：谨防诈骗